THERASPHERE Y-90
Report
- Report Number
- 2124215-2024-84218
- Event Type
- Injury
- Date Received
- January 21, 2025
- Date of Event
- September 11, 2024
- Report Date
- May 21, 2026
- Manufacturer
- BOSTON SCIENTIFIC CORPORATION
- Product Code
- NAW
- Adverse Event
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- CH
- Reporter Occupation
- PHYSICIAN
- Health Professional
- Yes
Narratives
D3, MANUFACTURER ZIP/POSTAL: GU9 8QL.
IT WAS REPORTED THAT THE PATIENT HAD SYMPTOMS THAT WERE TREATED WITH PRESCRIPTION MEDICATION. ON (B)(6) 2024, THE SUBJECT WAS RANDOMIZED (THERASPHERE ARM) IN THE MANDARIN STUDY (MAIN PHASE) WITH THE PLANNED TREATMENT TYPE WAS UNI-LOBAR TREATMENT. TREATMENT WITH THERASPHERE WAS PERFORMED ON (B)(6) 2024; 99MTC-MAA ANGIOGRAM WAS PERFORMED, AND TARGET VOLUME WAS 624 CM3 AND 14.73 GBQ WAS ADMINISTERED THROUGH 1 VIAL. TOTAL ACTIVITY OF THERASPHERE DELIVERY TO LUNG WAS 0.17 GBQ. RADIATION DOSE TO PERFUSED LIVER TISSUE, AND DOSE TO PERFUSED TARGET TUMOR TISSUE WAS DETAILS WERE NOT AVAILABLE AT THE TIME OF REPORTING. A RE-TREATMENT WITH THERASPHERE WAS PERFORMED ON (B)(6) 2024 WITH THE PLANNED TREATMENT TYPE WAS SELECTIVE TREATMENT. TARGET VOLUME WAS 177.94 CM3 AND 5.96 GBQ WAS ADMINISTERED THROUGH 1 VIAL. TOTAL ACTIVITY OF THERASPHERE DELIVERY TO LUNG WAS 0.183 GBQ AND TOTAL ACTIVITY OF THERASPHERE DELIVERY TO PERFUSED LIVER TISSUE 2.167 GBQ. RADIATION DOSE TO PERFUSED LIVER TISSUE WAS 593 GY AND RADIATION DOSE TO LUNGS WAS 9.1GY. ON (B)(6) 2024, SUBJECT EXPERIENCED MALAISE, ANOREXIA, AND NAUSEA. NO CORRECTIVE ACTION WAS TAKEN TO TREAT THE EVENT OF MALAISE; HOWEVER, MEGESTROL ACETATE DISPERSIBLE TABLETS WERE ADMINISTERED TO TREAT ANOREXIA AND BOTH ONDANSETRON HYDROCHLORIDE TABLETS AND ESOMEPRAZOLE MAGNESIUM ENTERIC-COATED TABLETS WERE ADMINISTERED TO TREAT NAUSEA.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 620924 | THERASPHERE Y-90 | MICROSPHERES RADIONUCLIDE | NAW | BOSTON SCIENTIFIC CORPORATION | 2499393 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |